Natco Pharma Ltd.

NSE: NATCOPHARM | BSE: 524816 | ISIN: INE987B01026 | Industry: Pharmaceuticals
| Value Stock, Under Radar
846.1000 -6.65 (-0.78%)
NSE Sep 08, 2025 15:31 PM
Volume: 349.1K
 

logo
Natco Pharma Ltd.
15 Feb 2019
846.10
-0.78%
Geojit BNP Paribas
EBITDA margin was down by 1200bps on account of lower margin realisation from Oseltamivir sales in the US (treatment for flu). Initiated work on green-field manufacturing facilities for producing niche agrichemicals with focus on formulation products. Launched Valsartan-Sacubitril tablet in India and filed ANDA for generic version of Ibrutinib tablets in the US . We revise downward our Revenue/PAT estimates by 4%/3% for FY20 to factor lower sales from the US....
Number of MF schemes decreased from 54 to 47 in Jun 2025 qtr
More from Natco Pharma Ltd.
Recommended